Molecular diagnosis and monitoring of acute myeloid leukemia

Leukemia Research

Volumn 20, Issue 10, 1996, Pages 801-807

  Biondi, Andrea ^a,b   Rambaldi, Alessandro ^a  

^a OSPEDALI RIUNITI   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

Acute myeloid leukemia; Genes; Leukemia; Minimal residual disease; Translocations

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME 11Q; CHROMOSOME 16; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; HUMAN; MOLECULAR BIOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW;

EID: 0030271575     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(96)00022-7     Document Type: Review

References (47)

1. 1. Rabbitts T. H. (1994) Chromosomal translocations in human cancer. Nature 372, 143.
2. 2. Cline M. J. (1994) The molecular basis of leukemia. N. Engl. J. Med. 330, 328.
3. 3. Zeleznik-Le N., Nucifora G. & Rowley J. D. (1995) The molecular biology of myeloproliferative disorders as revealed by chromosomal abnormalities. Semin. Hematol. 32, 201.
4. 4. Sklar J. (1991) Polymerase chain reaction: the molecular microscope of residual disease. J. Clin. Oncol. 9, 1521.
5. 5. Grignani F., Fagioli M., Alcalay M., Longo L., Pandolfi P. P., Donti E., Biondi A., Lo Coco F. & Pelicci P. G. (1994) Acute promyelocytic leukemia: from genetics to treatment. Blood 83, 10.
6. 6. Pandolfi P. P., Alcalay M., Fagioli M., Zangrilli D., Mencarelli A., Diverio D., Biondi A., Lo Coco F., Rambaldi A., Grignani F., Rochette-Egly C., Gaube M. P., Chambon P. & Pelicci P. G. (1992) Genomic variability and alternative splicing generate multiple PML/RARα transcripts that encode aberrant PML proteins and PML/ RARα isoforms in acute promyelocytic leukemia. EMBO J. 1, 1397.
7. 7. Alcalay M., Zangrilli D., Fagioli M., Pandolfi P. P., Mencarelli A., Lo Coco F., Biondi A., Grignani F. & Pelicci P. G. (1992) Expression pattern of the RARα-PML fusion gene in acute promyelocytic leukemia. Proc. Natl Acad. Sci. U.S.A. 89, 4840.
8. 8. Chang K. S., Lu J., Wang G., Trujillo J. M., Estey E., Cork A., Chu D. T., Freireich E. J. & Stass S. A. (1992) The t(15;17) breakpoint in acute promyelocytic leukemia cluster within two different sites of the myl gene: targets for the detection of minimal residual disease by polymerase chain reaction. Blood 79, 554.
9. 9. Castaigne S., Balitrand N., Thé H. de, Dejean A., Degos L. & Chomienne C. (1992) A PML-retinoic acid receptor alpha fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocitic leukemia. Blood 79, 3110.
10. 10. Chen S. J., Chen Z., Chen A., Tong J. H., Dong S., Wang Z. Y., Waxman S. & Zelent A. (1992) Occurrence of distinct PML-RARalfa isoforms in patients with acute promyelocytic leukemia detected by reverse transcriptase/ polymerase chain reaction. Oncogene 7, 1223.
11. 11. Biondi A., Rambaldi A., Pandolfi P. P., Rossi V., Giudici G., Alcalay M., Lo Coco F., Diverio D., Pogliani E. M., Lanzi E. M., Mandelli F., Masera G., Barbui T. & Pelicci P. G. (1992) Molecular monitoring of the myl/RAR-α fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 80, 492.
12. 12. Chen S. J., Zelent A., Tong J. H., Huai-Qin Y., Wang Z. Y., Derré J., Berger R., Waxman S. & Chen Z. (1993) Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17) (q23;q21) in a patient with acute promyelocytic leukemia. J. Clin. Invest. 91, 2260.
13. 13. Licht J.D., Chomienne C., Goy A. et al. (1995) Clinical and molecular characterization of acute promyelocytic leukemia with translocation t(11;17). Blood 85, 1083.
14. 14. Bernard O. A. & Berger R. (1995) Molecular basis of 11q23 rearrangements in hematopoietic malignant proliferations. Genes, Chromosomes Cancer 13, 75.
15. 15. Tkachuk D. C., Kohler S. & Cleary M. L. (1992) Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 71, 691.
16. 16. Gu Y., Nakamura T., Alder H., Prasad R., Canaani O., Cimino G., Croce C. M. & Cananni E. (1992) Translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 71, 701.
17. 17. Thirman M. I., Gill H. J., Burnett R. C., Mbangkollo D., McCabe N. R., Kobayashi H., Ziemin van der Poel S., Kaneko Y., Morgan R. & Sandberg A. A. (1994) Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N. Eng. J. Med. 329, 909.
18. 18. Arthur D. C., Berger R., Golomb H. M., Swansbury G. J., Reeves R. R., Alimena G., Van den Berghe H., Bloomfield C. D., Chapelle A. de la, Dewald G. W., Garson O. M., Hagemeijer A., Kanako Y., Mitlman F., Pierre R. V., Ruutu T., Sakurai M., Lawler D. D. & Rowley J. D. (1989) The clinical significance of karyotype in acute mylogenous leukemia. Cancer Genet. Cytogenet. 40, 203.
19. 19. Kita K., Shirakawa S. & Kamada N. (1994) Cellular characteristics of acute myeloblastic leukemia associated with t(8;21) (q22;q22). Leukemia Lymphoma 13, 229.
20. 20. Nucifora G. & Rowley J. D. (1995) AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 86, 1.
21. 21. Liu P., Tarle S. A., Haira A., Claxton D. F., Marlton P., Freedman M., Siciliano M. I. & Collins F. S. (1993) Fusion between transcription factor CBFb/PEBP2b and myosin heavy chain in acute myeloid leukemia. Science 261, 1041.
22. 22. Liu P. P., Hajra A., Wijmenga C. & Collins F. S. (1995) Molecular pathogenesis of the chromosome 16 inversion in the M4eo subtype of acute myeloid leukemia. Blood 85, 2289.
23. 23. Poirel H., Radford-Weiss I. & Rack K. et al. (1995) Detection of the chromosome 16 CBFβ/MYH11 fusion transcript in myelomonocytic leukemias. Blood 85, 1313.
24. 24. Lindern M. von, Poustka A., Lerach H. & Grosveld G. (1990) The (6;9) chromosome translocation associated with a specific subtype of acute nonlymphocytic leukemia, leads to aberrant transcription of a target gene on 89 q34. Mol. Cell Biol. 10, 4016.
25. 25. Keating M. J., Cork A., Broach Y., Smith T., Walters R. S., McCredie K. B., Trujillo J. & Freireich E. (1987) Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leukemia Res. 11, 119.
26. 26. Keating M. J., Smith T. L., Kantarjian H., Cork A., Walters R., Trujillo J. M., McCredie K. B., Gehan E. A. & Freireich E. J. (1988) Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 2, 403.
27. 27. Bloomfield C. D., Lawrence D., Arthur D. C., Berg D. T., Schiffer C. A. & Mayer R. J. (1994) Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 84, 111.
28. 28. Creutzig U., Ritter J. & Schellong G. (1990) Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. Blood 75, 1932.
29. 29. Yates J., Glidewell O., Wiernik P., Cooper M. R., Steinberg D., Dosik H., Levy R., Hoagland C., Henry P., Gottlieb A., Cornell C., Berenberg J., Hutchison J. L., Raich P., Nissen N., Ellison R. R., Frelick R., James G. W., Falkson G., Silver R. T., Haurani F., Green M., Henderson E., Leone L. & Holland J. F. (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60, (2), 454.
30. 30. Wiernik P. H., Banks P. L. C., Case D. C. Jr., Arlin Z. A., Periman P. O., Todd M. B., Ritch P. S., Enck R. E. & Weitberg A. B. (1992) Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79, 313.
31. 31. Warrel R. P., De Thé H., Wang Z. Y. & Degos L. (1993) Acute promyelocytic leukemia. N. Engl. J. Med. 329, 177.
32. 32. Tallman M. S., Andersen J., Schiffer C. A., Appelbaum F. R., Feusner J. E., Woods W. G., Ogden A., Weinstein H., Shepherd L., Rowe J. M. & Wiernik P. H. (1995) Phase III randomized study of all-trans retinoic acid (ATRA) vs daunorubicin (D) and cytosine arabinoside (A) as induction therapy and ATRA vs observation as maintenance therapy for patients with previously untreated acute promyelocytic leukemia (APL) Blood 86, 125a.
33. 33. Fenaux P., Chastang C., Chomienne C., Castaigne S., Sanz M., Link H., Lowenberg B., Fey M., Archim-Baud E., Degos L. & The European APL Group (1995) Treatment of newly diagnosed acute promyelocytic leukemia (APL) by A11 transretinoic acid (ATRA) combined with chemotherapy: the European experience. Leukemia Lymphoma 16, 431.
34. 34. Lo Coco F., Diverio D., Avvisati G., Luciano A., Biondi A. & Mandelli F. (1995) High frequency of early molecular remission in acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (Italian GIMEMA-AIEOP "AIDA" trial). Blood 86, 265a.
35. 35. Mayer R. J. (1988) Allogenic transplantation versus intensive chemotherapy in first-remission acute leukemia: is there a "best choice". J. Clin. Oncol. 6, 1532.
36. 36. Mayer R. J., Davis R. B., Schiffer C. A., Bergm T. D., Powell B. L., Schulman P., Omura G. A., Moore J. O., McIntyre O. R. & Frei III E. (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med. 331, 896.
37. 37. Campana D. & Pui C. H. (1995) Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 85, 1416.
38. 38. Lo Coco F., Diverio D., Pandolfi P. P., Biondi A., Rossi V., Avvisati G., Rambaldi A., Arcese W., Petti M. C., Meloni G., Mandelli F., Grignani F., Masera T., Barbui T. & Pelicci P. G. (1992) PCR evaluation of residual disease as a predictor of cure or relapse in acute promyelocytic leukemia. Lancet 340, 1437.
39. 39. Miller W. H. Jr., Kakizuka A., Frankel S. R., Warrel R. P. Jr., De Blasio A., Levine K., Evans R. M. & Dimitrovski E. (1992) Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc. Natl Acad. Sci. U.S.A. 89, 2694.
40. 40. Huang W., Sun G. L., Li X. S., Cao Q., Lu Y, Jang G. S., Zhang F. Q., Chai J. R., Wang Z. Y., Waxman S., Chen Z. & Chen S. J. (1993) Acute promyelocytic leukemia: clinical relevance of two major PML/RARalfa isoforms and detection of minimal residual disease by retrotranscriptase polymerase chain reaction to predict relapse. Blood 82, 1264.
41. 41. Kawasaki E. S., Clark S. S., Coyne M. Y., Smith S. D., Champlin R., Witte D. N. & McCormick F. P. (1988) Diagnosis of chronic myeloid and acute lymphocytic leukemia by detection of leukemia-specific mRNA sequences amplified in vitro. Proc. Natl Acad. Sci U.S.A. 85, 5698.
42. 42. Nucifora G., Larson R. A., & Rowley J. D. (1993) Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 82, 712.
43. 43. Claxton D. F., Liu P. & Hsu H. B. et al. (1994) Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood 83, 1750.
44. 44. Chang K. S., Fan Y. H. & Stass S. A. et al. (1993) Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8,21) positive acute myeloid leukemia. Oncogene 8, 983.
45. 45. Maruyama F., Yang P. & Stass S. A. et al. (1993) Detection of the AML1/ETO fusion transcript in the t(8;21) masked translocation in acute myelogenous leukemia. Cancer Res. 53, 4449.
46. 46. Kusek R., Laczika K. & Knobl P. et al. (1994) AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 8, 735.
47. 47. Hebert J., Cayuela J. M. & Daniel M. T. et al. (1994) Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal marrow eosinophil by nested polymerase chain reaction with allele specific amplification. Blood 84, 2291.